News and Events
Celebrating CCR Careers: Zhengping Zhuang, M.D., Ph.D.
Zhengping Zhuang, M.D., Ph.D., is a world-renowned expert in experimental pathology, cancer genetics and cancer therapeutics. He has contributed to biotechnological advancements, drug development and clinical translation of his work in tumor biology. After 32 years serving the NCI, he has announced his retirement.
Read MoreCelebrating CCR Careers: Kenneth H. Kraemer, M.D.
For more than fifty years, Kenneth H. Kraemer, M.D., has investigated the molecular underpinnings and clinical manifestations of xeroderma pigmentosum, a rare disease that makes children highly vulnerable to skin damage and cancers from ultraviolet radiation, at the NCI.
Read MoreMolecular signature can identify tumor-targeting immune cells in the blood
Blood samples could be a new source of antitumor T cells for customized cancer immunotherapies.
Read MoreClinical trial researching olfactory neuroblastoma
A clinical trial led by Charalampos S. Floudas, M.D., D.M.Sc., M.S., Assistant Research Physician in the Center for Immuno-Oncology, is researching the symptoms and characteristics of olfactory neuroblastoma.
Read MoreNovel T cell stimulation technique drives potent anti-tumor response
Researchers combined an antibody with an immune-signaling molecule resulting in an agent called STAR0602. A version of the novel agent was designed for and tested in mice, which induced significant tumor shrinkage and increased survival across six different types of cancer while exhibiting little toxicity. The promising lab findings have prompted the launch of a clinical trial in people.
Read MoreExperimental vaccine halts respiratory growths from HPV infection
An experimental vaccine that trains a patient’s immune system to recognize HPV-infected cells could potentially be used to treat people with recurrent respiratory papillomatosis, according to results from an ongoing clinical trial.
Read MoreInactivating the WRN protein could kill colorectal and other cancer cells
Rapid inactivation of the Werner Syndrome helicase (WRN), a protein upon which cancer cells that exhibit microsatellite instability often rely for survival, could be effective in killing colorectal and other cancer cells and potentially guide the development of inhibitor drugs.
Read MoreIn Memoriam: S. Perwez Hussain, Ph.D. (1960 - 2023)
The CCR community is profoundly saddened by the passing of S. Perwez Hussain, Ph.D., Senior Investigator in the Laboratory of Human Carcinogenesis. He died on November 24, 2023, after living with stage 4 colon cancer for many years.
Read MoreFDA grants orphan drug designation to indotecan for the treatment of glioma
The U.S. Food and Drug Administration (FDA) granted orphan drug status to LMP400 (indotecan) for use in patients with malignant glioma, a cancer of the brain that begins in glial cells (cells that surround and support nerve cells).
Read MoreClinical trial researches combination drug therapy for myelodysplastic syndromes
A clinical trial led by Steven Z. Pavletic, M.D., Ph.D., Senior Clinician in the Immune Deficiency Cellular Therapy Program, is researching a combination drug therapy for myelodysplastic syndromes.
Read MoreSix years after preventive surgery: a patient’s future without stomach cancer
Faced with a high risk of developing stomach cancer, David Fogel chose to undergo preventive surgery as part of an NIH research study. Six years later, David is thriving, and so is the research that was made possible by his participation.
Read More